News

MyChesCo on MSN9h
AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBC
AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® ...
CURE18h
Bladder Cancer Awareness Month Highlights the Importance of Early Detection
Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...
MedPage Today on MSN2d
First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer
First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...
Endpoints News3d
Ax­some's $570M loan with Black­stone; Al­tim­mune makes its own cred­it deal
Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.
PMLive3d
AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer
The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...
Clinical Trials Arena4d
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...